Showing posts with label Europe Topical Drug Delivery Market. Show all posts
Showing posts with label Europe Topical Drug Delivery Market. Show all posts

Europe Topical Drug Delivery Market Segmented by Product Type, Distribution Channel, End User & Geography

The report “Europe Topical Drug Delivery Market is expected to reach USD 60.3 billion by 2024 from USD 31.3 billion in 2016, growing at a CAGR of 8.5% in the forecast period 2017 to 2024”, also the Europe Topical Drug Delivery Market, By Product Type {Topical (Solid, Liquid, Semi-Solid), Transdermal (Patches, Gels)}, End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers), Distribution Channel (Direct Tenders, Retail), Country (Germany, France, U.K., Belgium, Switzerland, Italy, Spain, Russia, Turkey, Netherlands and Rest of Europe) – Trends and Forecast to 2024


This report consists of below pages:

•             No of pages: 175
•             No of Figures: 30
•             No of Tables: 125


The Europe Topical Drug Delivery Market is segmented on the basis of product type, distribution channel, end user, and geography.

The key companies involved in this market are:

·         MedPharm
·         Janssen Pharmaceuticals, Inc.,(Johnson & Johnson Services Inc.)
·         Crescita TherapeuticsiNC.
·         Galderma S.A.
·         Biofarmitalia s.r.l
·         Pharmatek Laboratories, Inc.
·         Stiefel Laboratories, Inc.
·         Tapemark
·         Acrux Limited
·         Nitto Denko Corporation
·         Valeant Pharmaceuticals International, Inc.
·         Skinvisible Pharmaceuticals, Inc.
·         Mylan Pharmaceuticals Inc.
·         Hisamitsu Pharmaceutical Co., Inc.
·         Pocono Coated Products LLC
·         TheraSolve NV.
·         Samyang Biopharmaceuticals Corporation
·         Lohmann Therapie-Systeme AG
·         Prosollus Pharmaceuticals
·         Easton Pharmaceuticals Inc.
·         Novosis AG
·         Antares Pharma, Inc.
·         Endo Pharmaceuticals Inc.
·         Transdermal Technologies, Inc.
·         Sheffield Pharmaceuticals, Inc.
·         Solvay
·         3M Drug Delivery Systems.


Report Segmentation:

On the basis of product type, the Europe Topical Drug Delivery Market is segmented into transdermal drug delivery devices and topical drug delivery formulations. Topical drug delivery formulations are further segmented based on form into solid, semi-solid, and liquid. The semi solid segment is further classified into ointments, creams, lotions, gels, and pastes. The solid drugs segment is further segmented into powders and suppositors. The liquid drugs segment is further classified into solutions and suspensions.

The transdermal drug delivery devices market segment is further segmented into patches and gels.

On the basis of end users, the Europe Topical Drug Delivery Market is segmented into hospitals, home healthcare, clinics, diagnostic centers, and others.

Based on country, the Europe Topical Drug Delivery Market is segmented into Germany, France, United Kingdom., Belgium, Switzerland, Italy, Spain, Russia, Turkey, Netherlands and Rest of Europe. The Europe topical drug delivery market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.


Table of Contents:

1. INTRODUCTION
      1.1. OVERVIEW OF THE EUROPE TOPICAL DRUG DELIVERY MARKET
      1.2. MARKET SEGMENTATION & COVERAGE
2. RESEARCH METHODOLOGY
      2.1. KEY TAKEAWAYS
     2.2. ARRIVING AT THE EUROPE TOPICAL DRUG DELIVERY MARKET SIZE
     2.4. EUROPE TOPICAL DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
     2.5. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
       4.1. OVERVIEW
       4.2. EUROPE TOPICAL DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
       4.3. MARKET OVERVIEW
       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. EXECUTIVE SUMMARY
6. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
        6.1. OVERVIEW
        6.2. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
7. TOPICAL DRUG DELIVERY MARKET, BY END-USER
        7.1. OVERVIEW
        7.2. HOSPITALS
        7.3. HOME HEALTHCARE
        7.4. CLINICS
        7.5. DIAGNOSTIC CENTERS
        7.6. OTHERS
8. TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
        8.1. OVERVIEW
       8.2. HOSPITAL PHARMACIES
       8.3. PHARMACY STORES
       8.4. DIRECT TENDERS
       8.5. ONLINE PHARMACY
9. TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY
      9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10. TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
            10.1. EUROPE TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.2. U.S. TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.4. APAC TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.5. SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.6. MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.7. MERGERS & ACQUISITIONS
            10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
            10.10. EXPANSIONS
            10.10. REGULATORY CHANGES
            10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11. TOPICAL DRUG DELIVERY MARKET, COMPANY PROFILES
          11.1. JANSSEN PHARMACEUTICALS, INC. (A J&J COMPANY)
                     11.1.1. COMPANY OVERVIEW
                     11.1.2. SWOT ANALYSIS
                     11.1.3. REVENUE ANALYSIS
                     11.1.4. PRODUCT PORTFOLIO
                     11.1.5. RECENT DEVELOPEMENTS
                     11.1.5. DATA BRIDGE ANALYSIS
         11.2. CRESCITA THERAPEUTICS
                    11.2.1. COMPANY OVERVIEW
                    11.2.2. SWOT ANALYSIS
                    11.2.3. REVENUE ANALYSIS
                    11.2.4. PRODUCT PORTFOLIO
                    11.2.5. RECENT DEVELOPEMENTS
                    11.2.5. DATA BRIDGE ANALYSIS
         11.3. GALDERMA S.A.
                    11.3.1. COMPANY OVERVIEW
                    11.3.2. SWOT ANALYSIS
                    11.3.3. REVENUE ANALYSIS
                    11.3.4. PRODUCT PORTFOLIO
                    11.3.5. RECENT DEVELOPEMENTS
                    11.3.6. DATA BRIDGE ANALYSIS
         11.4. BIOFARMITALIA S.R.L
                    11.4.1. COMPANY OVERVIEW
                    11.4.2. SWOT ANALYSIS
                    11.4.3. REVENUE ANALYSIS
                    11.4.4. PRODUCT PORTFOLIO
                    11.4.5. RECENT DEVELOPEMENTS
                    11.4.5. DATA BRIDGE ANALYSIS
         11.5. PHARMATEK LABORATORIES, INC.
                    11.5.1. COMPANY OVERVIEW
                    11.5.2. SWOT ANALYSIS
                    11.5.3. REVENUE ANALYSIS
                    11.5.4. PRODUCT PORTFOLIO
                    11.5.5. RECENT DEVELOPEMENTS
                    11.5.5. DATA BRIDGE ANALYSIS
         11.6. STIEFEL LABORATORIES, INC.
                    11.6.1. COMPANY OVERVIEW
                    11.6.2. SWOT ANALYSIS
                    11.6.3. REVENUE ANALYSIS
                    11.6.4. PRODUCT PORTFOLIO
                    11.6.5. RECENT DEVELOPEMENTS
                    11.6.5. DATA BRIDGE ANALYSIS
         11.7. TAPEMARK
                    11.7.1. COMPANY OVERVIEW
                    11.7.2. SWOT ANALYSIS
                    11.7.3. REVENUE ANALYSIS
                    11.7.4. PRODUCT PORTFOLIO
                    11.7.5. RECENT DEVELOPEMENTS
                    11.7.6. DATA BRIDGE ANALYSIS
         11.8. NITTO DENKO CORPORATION
                    11.8.1. COMPANY OVERVIEW
                    11.8.2. SWOT ANALYSIS
                    11.8.3. REVENUE ANALYSIS
                    11.8.4. PRODUCT PORTFOLIO
                    11.8.5. RECENT DEVELOPEMENTS
                    11.8.6. DATA BRIDGE ANALYSIS
         11.9. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
                    11.9.1. COMPANY OVERVIEW
                    11.9.2. SWOT ANALYSIS
                    11.9.3. REVENUE ANALYSIS
                    11.9.4. PRODUCT PORTFOLIO
                    11.9.5. RECENT DEVELOPEMENTS
                    11.9.6. DATA BRIDGE ANALYSIS
         11.9. MYLAN PHARMACEUTICALS INC.
                    11.9.1. COMPANY OVERVIEW
                    11.9.2. SWOT ANALYSIS
                    11.9.3. REVENUE ANALYSIS
                    11.9.4. PRODUCT PORTFOLIO
                    11.9.5. RECENT DEVELOPEMENTS
                    11.9.6. DATA BRIDGE ANALYSIS
         11.9. HISAMITSU PHARMACEUTICAL CO., INC.
                     11.9.1. COMPANY OVERVIEW
                     11.9.2. SWOT ANALYSIS
                     11.9.3. REVENUE ANALYSIS
                     11.9.4. PRODUCT PORTFOLIO
                     11.9.5. RECENT DEVELOPEMENTS
                     11.9.5. DATA BRIDGE ANALYSIS
         11.10. THERASOLVE NV.
                       11.10.1. COMPANY OVERVIEW
                       11.10.2. SWOT ANALYSIS
                       11.10.3. REVENUE ANALYSIS
                       11.10.4. PRODUCT PORTFOLIO
                       11.10.5. RECENT DEVELOPEMENTS
                       11.10.6. DATA BRIDGE ANALYSIS
         11.11. SAMYANG BIOPHARMACEUTICALS CORPORATION
                       11.11.1. COMPANY OVERVIEW
                       11.11.2. SWOT ANALYSIS
                       11.11.3. REVENUE ANALYSIS
                       11.11.4. PRODUCT PORTFOLIO
                       11.11.5. RECENT DEVELOPEMENTS
                       11.11.6. DATA BRIDGE ANALYSIS
         11.12. LOHMANN THERAPIE-SYSTEME AG
                       11.12.1. COMPANY OVERVIEW
                       11.12.2. SWOT ANALYSIS
                       11.12.3. REVENUE ANALYSIS
                       11.12.4. PRODUCT PORTFOLIO
                       11.12.5. RECENT DEVELOPEMENTS
                       11.12.6. DATA BRIDGE ANALYSIS
         11.13. PROSOLLUS PHARMACEUTICALS
                       11.13.1. COMPANY OVERVIEW
                       11.13.2. SWOT ANALYSIS
                       11.13.3. REVENUE ANALYSIS
                       11.13.4. PRODUCT PORTFOLIO
                       11.13.5. RECENT DEVELOPEMENTS
                       11.13.6. DATA BRIDGE ANALYSIS
         11.14. EASTON PHARMACEUTICALS INC.
                       11.14.1. COMPANY OVERVIEW
                       11.14.2. SWOT ANALYSIS
                       11.14.3. REVENUE ANALYSIS
                       11.14.4. PRODUCT PORTFOLIO
                       11.14.5. RECENT DEVELOPEMENTS
                       11.14.6. DATA BRIDGE ANALYSIS
         11.15. ANTARES PHARMA, INC.
                       11.15.1. COMPANY OVERVIEW
                       11.15.2. SWOT ANALYSIS
                       11.15.3. REVENUE ANALYSIS
                       11.15.4. PRODUCT PORTFOLIO
                       11.15.5. RECENT DEVELOPEMENTS
                      11.15.6. DATA BRIDGE ANALYSIS
         11.16. ENDO PHARMACEUTICALS INC.
                       11.16.1. COMPANY OVERVIEW
                       11.16.2. SWOT ANALYSIS
                       11.16.3. REVENUE ANALYSIS
                       11.16.4. PRODUCT PORTFOLIO
                       11.16.5. RECENT DEVELOPEMENTS
                       11.16.6. DATA BRIDGE ANALYSIS
         11.17. TRANSDERMAL TECHNOLOGIES, INC.
                       11.17.1. COMPANY OVERVIEW
                       11.17.2. SWOT ANALYSIS
                       11.17.3. REVENUE ANALYSIS
                       11.17.4. PRODUCT PORTFOLIO
                       11.17.5. RECENT DEVELOPEMENTS
                       11.17.6. DATA BRIDGE ANALYSIS
         11.18. SHEFFIELD PHARMACEUTICALS, INC.
                       11.18.1. COMPANY OVERVIEW
                       11.18.2. SWOT ANALYSIS
                       11.18.3. REVENUE ANALYSIS
                       11.18.4. PRODUCT PORTFOLIO
                       11.18.5. RECENT DEVELOPEMENTS
                       11.18.6. DATA BRIDGE ANALYSIS
         11.19. SOLVAY
                       11.19.1. COMPANY OVERVIEW
                       11.19.2. SWOT ANALYSIS
                       11.19.3. REVENUE ANALYSIS
                       11.19.4. PRODUCT PORTFOLIO
                       11.19.5. RECENT DEVELOPEMENTS
                       11.19.6. DATA BRIDGE ANALYSIS
         11.20. 3M DRUG DELIVERY SYSTEMS
                       11.20.1. COMPANY OVERVIEW
                       11.20.2. SWOT ANALYSIS
                       11.20.3. REVENUE ANALYSIS
                       11.20.4. PRODUCT PORTFOLIO
                       11.20.5. RECENT DEVELOPEMENTS
                       11.20.6. DATA BRIDGE ANALYSIS

Related Report

Global Topical Drug Delivery Market – Trends and Forecast to 2024

Global Topical Drug Delivery Market, By Product Type {Topical (Solid, Liquid, Semi-Solid), Transdermal (Patches, Gels)}; End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Others); Distribution Channel (Direct Tenders, Retail); Geography (North America, Europe, Asia-Pacific, Latin America, Rest of the World) – Trends and Forecast to 2024


About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Follow us on LinkedIn: https://www.linkedin.com/company/data-bridge-market-research
Europe Topical Drug Delivery Market Size & Growth USD 60.3 Billion by 2024

Europe Topical Drug Delivery Market Size & Growth USD 60.3 Billion by 2024

Europe Topical Drug Delivery Market, By Product Type {Topical (Solid, Liquid, Semi-Solid), Transdermal (Patches, Gels)}, End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers), Distribution Channel (Direct Tenders, Retail), Country (Germany, France, U.K., Belgium, Switzerland, Italy, Spain, Russia, Turkey, Netherlands and Rest of Europe) – Trends and Forecast to 2024

Europe Topical Drug Delivery Market is expected to reach USD 60.3 billion by 2024 from USD 31.3 billion in 2016, growing at a CAGR of 8.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Request for Sample Report Visit @ http://databridgemarketresearch.com/request-a-sample/?dbmr=europe-topical-drug-delivery-market-trends-forecast24

Some of the major companies operating in this market are:
·         MedPharm
·         Janssen Pharmaceuticals, Inc.,(Johnson & Johnson Services Inc.)
·         Crescita TherapeuticsiNC.
·         Galderma S.A.
·         Biofarmitalia s.r.l
·         Pharmatek Laboratories, Inc.
·         Stiefel Laboratories, Inc.
·         Tapemark
·         Acrux Limited
·         Nitto Denko Corporation
·         Valeant Pharmaceuticals International, Inc.
·         Skinvisible Pharmaceuticals, Inc.
·         Mylan Pharmaceuticals Inc.
·         Hisamitsu Pharmaceutical Co., Inc.
·         Pocono Coated Products LLC
·         TheraSolve NV.
·         Samyang Biopharmaceuticals Corporation
·         Lohmann Therapie-Systeme AG
·         Prosollus Pharmaceuticals
·         Easton Pharmaceuticals Inc.
·         Novosis AG
·         Antares Pharma, Inc.
·         Endo Pharmaceuticals Inc.
·         Transdermal Technologies, Inc.
·         Sheffield Pharmaceuticals, Inc.
·         Solvay
·         3M Drug Delivery Systems.

The Europe Topical Drug Delivery Market is segmented on the basis of product type, distribution channel, end user, and geography.

On the basis of product type, the Europe Topical Drug Delivery Market is segmented into transdermal drug delivery devices and topical drug delivery formulations. Topical drug delivery formulations are further segmented based on form into solid, semi-solid, and liquid. The semi solid segment is further classified into ointments, creams, lotions, gels, and pastes. The solid drugs segment is further segmented into powders and suppositors. The liquid drugs segment is further classified into solutions and suspensions.

The transdermal drug delivery devices market segment is further segmented into patches and gels. In 2016, on the basis of product type topical drug delivery formulations segment dominated the market by 72.6% share, however transdermal drug delivery devices market is expected to grow at the highest CAGR of 14.1% in the forecast period 2017 to 2024.

On the basis of end users, the Europe Topical Drug Delivery Market is segmented into hospitals, home healthcare, clinics, diagnostic centers, and others.

Based on country, the Europe Topical Drug Delivery Market is segmented into Germany, France, United Kingdom., Belgium, Switzerland, Italy, Spain, Russia, Turkey, Netherlands and Rest of Europe. The Europe topical drug delivery market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.


Table of Content:

1. INTRODUCTION
      1.1. OVERVIEW OF THE EUROPE TOPICAL DRUG DELIVERY MARKET
      1.2. MARKET SEGMENTATION & COVERAGE
2. RESEARCH METHODOLOGY
      2.1. KEY TAKEAWAYS
     2.2. ARRIVING AT THE EUROPE TOPICAL DRUG DELIVERY MARKET SIZE
     2.4. EUROPE TOPICAL DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
     2.5. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
       4.1. OVERVIEW
       4.2. EUROPE TOPICAL DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
       4.3. MARKET OVERVIEW
       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. EXECUTIVE SUMMARY
6. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
        6.1. OVERVIEW
        6.2. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
                 6.2.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
                            6.2.1.1. TRANSDERMAL PATCHES
                            6.2.1.2. TRANSDERMAL GELS
                           6.2.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
                           6.2.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
                           6.2.2.1.1. SOLUTIONS
                           6.2.2.1.2.  SUSPENSIONS
                           6.2.2.2.  SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
                           6.2.2.2.1.  GELS
                           6.2.2.2.2.  CREAMS
                           6.2.2.2.3.  OINTMENTS
                           6.2.2.2.4.  PASTES
                           6.2.2.2.5.  LOTIONS
                           6.2.2.3.  SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
                           6.2.2.3.1.  SUPPOSITORIES
                           6.2.2.3.2.  POWDERS
7. TOPICAL DRUG DELIVERY MARKET, BY END-USER
        7.1. OVERVIEW
        7.2. HOSPITALS
        7.3. HOME HEALTHCARE
        7.4. CLINICS
        7.5. DIAGNOSTIC CENTERS
        7.6. OTHERS
8. TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
        8.1. OVERVIEW
       8.2. HOSPITAL PHARMACIES
       8.3. PHARMACY STORES
       8.4. DIRECT TENDERS
       8.5. ONLINE PHARMACY
9. TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY
      9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10. TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
            10.1. EUROPE TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.2. U.S. TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.4. APAC TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.5. SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.6. MIDDLE EAST AND AFRICA  TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.7. MERGERS & ACQUISITIONS
            10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
            10.10. EXPANSIONS
            10.10. REGULATORY CHANGES
            10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11. TOPICAL DRUG DELIVERY MARKET, COMPANY PROFILES
          11.1. JANSSEN PHARMACEUTICALS, INC. (A J&J COMPANY)
                     11.1.1. COMPANY OVERVIEW
                     11.1.2. SWOT ANALYSIS
                     11.1.3. REVENUE ANALYSIS
                     11.1.4. PRODUCT PORTFOLIO
                     11.1.5. RECENT DEVELOPEMENTS
                     11.1.5. DATA BRIDGE ANALYSIS
         11.2. CRESCITA THERAPEUTICS
                    11.2.1. COMPANY OVERVIEW
                    11.2.2. SWOT ANALYSIS
                    11.2.3. REVENUE ANALYSIS
                    11.2.4. PRODUCT PORTFOLIO
                    11.2.5. RECENT DEVELOPEMENTS
                    11.2.5. DATA BRIDGE ANALYSIS
         11.3. GALDERMA S.A.
                    11.3.1. COMPANY OVERVIEW
                    11.3.2. SWOT ANALYSIS
                    11.3.3. REVENUE ANALYSIS
                    11.3.4. PRODUCT PORTFOLIO
                    11.3.5. RECENT DEVELOPEMENTS
                    11.3.6. DATA BRIDGE ANALYSIS
         11.4. BIOFARMITALIA S.R.L
                    11.4.1. COMPANY OVERVIEW
                    11.4.2. SWOT ANALYSIS
                    11.4.3. REVENUE ANALYSIS
                    11.4.4. PRODUCT PORTFOLIO
                    11.4.5. RECENT DEVELOPEMENTS
                    11.4.5. DATA BRIDGE ANALYSIS
         11.5. PHARMATEK LABORATORIES, INC.
                    11.5.1. COMPANY OVERVIEW
                    11.5.2. SWOT ANALYSIS
                    11.5.3. REVENUE ANALYSIS
                    11.5.4. PRODUCT PORTFOLIO
                    11.5.5. RECENT DEVELOPEMENTS
                    11.5.5. DATA BRIDGE ANALYSIS
         11.6. STIEFEL LABORATORIES, INC.
                    11.6.1. COMPANY OVERVIEW
                    11.6.2. SWOT ANALYSIS
                    11.6.3. REVENUE ANALYSIS
                    11.6.4. PRODUCT PORTFOLIO
                    11.6.5. RECENT DEVELOPEMENTS
                    11.6.5. DATA BRIDGE ANALYSIS
         11.7. TAPEMARK
                    11.7.1. COMPANY OVERVIEW
                    11.7.2. SWOT ANALYSIS
                    11.7.3. REVENUE ANALYSIS
                    11.7.4. PRODUCT PORTFOLIO
                    11.7.5. RECENT DEVELOPEMENTS
                    11.7.6. DATA BRIDGE ANALYSIS
         11.8. NITTO DENKO CORPORATION
                    11.8.1. COMPANY OVERVIEW
                    11.8.2. SWOT ANALYSIS
                    11.8.3. REVENUE ANALYSIS
                    11.8.4. PRODUCT PORTFOLIO
                    11.8.5. RECENT DEVELOPEMENTS
                    11.8.6. DATA BRIDGE ANALYSIS
         11.9. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
                    11.9.1. COMPANY OVERVIEW
                    11.9.2. SWOT ANALYSIS
                    11.9.3. REVENUE ANALYSIS
                    11.9.4. PRODUCT PORTFOLIO
                    11.9.5. RECENT DEVELOPEMENTS
                    11.9.6. DATA BRIDGE ANALYSIS
         11.9. MYLAN PHARMACEUTICALS INC.
                    11.9.1. COMPANY OVERVIEW
                    11.9.2. SWOT ANALYSIS
                    11.9.3. REVENUE ANALYSIS
                    11.9.4. PRODUCT PORTFOLIO
                    11.9.5. RECENT DEVELOPEMENTS
                    11.9.6. DATA BRIDGE ANALYSIS
         11.9. HISAMITSU PHARMACEUTICAL CO., INC.
                     11.9.1. COMPANY OVERVIEW
                     11.9.2. SWOT ANALYSIS
                     11.9.3. REVENUE ANALYSIS
                     11.9.4. PRODUCT PORTFOLIO
                     11.9.5. RECENT DEVELOPEMENTS
                     11.9.5. DATA BRIDGE ANALYSIS
         11.10. THERASOLVE NV.
                       11.10.1. COMPANY OVERVIEW
                       11.10.2. SWOT ANALYSIS
                       11.10.3. REVENUE ANALYSIS
                       11.10.4. PRODUCT PORTFOLIO
                       11.10.5. RECENT DEVELOPEMENTS
                       11.10.6. DATA BRIDGE ANALYSIS
         11.11. SAMYANG BIOPHARMACEUTICALS CORPORATION
                       11.11.1. COMPANY OVERVIEW
                       11.11.2. SWOT ANALYSIS
                       11.11.3. REVENUE ANALYSIS
                       11.11.4. PRODUCT PORTFOLIO
                       11.11.5. RECENT DEVELOPEMENTS
                       11.11.6. DATA BRIDGE ANALYSIS
         11.12. LOHMANN THERAPIE-SYSTEME AG
                       11.12.1. COMPANY OVERVIEW
                       11.12.2. SWOT ANALYSIS
                       11.12.3. REVENUE ANALYSIS
                       11.12.4. PRODUCT PORTFOLIO
                       11.12.5. RECENT DEVELOPEMENTS
                       11.12.6. DATA BRIDGE ANALYSIS
         11.13. PROSOLLUS PHARMACEUTICALS
                       11.13.1. COMPANY OVERVIEW
                       11.13.2. SWOT ANALYSIS
                       11.13.3. REVENUE ANALYSIS
                       11.13.4. PRODUCT PORTFOLIO
                       11.13.5. RECENT DEVELOPEMENTS
                       11.13.6. DATA BRIDGE ANALYSIS
         11.14. EASTON PHARMACEUTICALS INC.
                       11.14.1. COMPANY OVERVIEW
                       11.14.2. SWOT ANALYSIS
                       11.14.3. REVENUE ANALYSIS
                       11.14.4. PRODUCT PORTFOLIO
                       11.14.5. RECENT DEVELOPEMENTS
                       11.14.6. DATA BRIDGE ANALYSIS
         11.15. ANTARES PHARMA, INC.
                       11.15.1. COMPANY OVERVIEW
                       11.15.2. SWOT ANALYSIS
                       11.15.3. REVENUE ANALYSIS
                       11.15.4. PRODUCT PORTFOLIO
                       11.15.5. RECENT DEVELOPEMENTS
                      11.15.6. DATA BRIDGE ANALYSIS
         11.16. ENDO PHARMACEUTICALS INC.
                       11.16.1. COMPANY OVERVIEW
                       11.16.2. SWOT ANALYSIS
                       11.16.3. REVENUE ANALYSIS
                       11.16.4. PRODUCT PORTFOLIO
                       11.16.5. RECENT DEVELOPEMENTS
                       11.16.6. DATA BRIDGE ANALYSIS
         11.17. TRANSDERMAL TECHNOLOGIES, INC.
                       11.17.1. COMPANY OVERVIEW
                       11.17.2. SWOT ANALYSIS
                       11.17.3. REVENUE ANALYSIS
                       11.17.4. PRODUCT PORTFOLIO
                       11.17.5. RECENT DEVELOPEMENTS
                       11.17.6. DATA BRIDGE ANALYSIS
         11.18. SHEFFIELD PHARMACEUTICALS, INC.
                       11.18.1. COMPANY OVERVIEW
                       11.18.2. SWOT ANALYSIS
                       11.18.3. REVENUE ANALYSIS
                       11.18.4. PRODUCT PORTFOLIO
                       11.18.5. RECENT DEVELOPEMENTS
                       11.18.6. DATA BRIDGE ANALYSIS
         11.19. SOLVAY
                       11.19.1. COMPANY OVERVIEW
                       11.19.2. SWOT ANALYSIS
                       11.19.3. REVENUE ANALYSIS
                       11.19.4. PRODUCT PORTFOLIO
                       11.19.5. RECENT DEVELOPEMENTS
                       11.19.6. DATA BRIDGE ANALYSIS
         11.20. 3M DRUG DELIVERY SYSTEMS
                       11.20.1. COMPANY OVERVIEW
                       11.20.2. SWOT ANALYSIS
                       11.20.3. REVENUE ANALYSIS
                       11.20.4. PRODUCT PORTFOLIO
                       11.20.5. RECENT DEVELOPEMENTS
                       11.20.6. DATA BRIDGE ANALYSIS

Related Report

Asia-Pacific (APAC) Infusion Pumps Market – Industry Trends and Forecast to 2024

Asia-Pacific (APAC) Infusion Pumps Market, By Product Types, By End-Users, By Distribution Channel, By Country (Japan, China, South Korea, India, Australia, Singapore, Thailand,  Malaysia, Indonesia, Phillipines, Rest of APAC) – Indutry Trends and Forecast to 2024

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Ankit Singh
Data Bridge Market Research
Tel: +1-888-387-2818
Follow us on LinkedIn: https://www.linkedin.com/company/data-bridge-market-research
Powered by Blogger.